{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:27:53Z","timestamp":1794025673359,"version":"4.8.0"},"reference-count":12,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            ABI-1648 (rifalazil) is a semisynthetic rifamycin with potent bactericidal activity against intracellular respiratory bacteria, including\n            <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n            , and a long half-life (\u223c60 h) and thus can be administered once weekly. We therefore tested the in vitro activities of ABI-1648, its derivatives ABI-1657 and ABI-1131, azithromycin, and levofloxacin against 10 strains of\n            <jats:italic>Chlamydia trachomatis<\/jats:italic>\n            and 10 recent clinical isolates of\n            <jats:italic>Chlamydia pneumoniae<\/jats:italic>\n            . The MICs at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed for ABI-1648, ABI-1657, and ABI-1131 were 0.0025 \u03bcg\/ml for\n            <jats:italic>C. trachomatis<\/jats:italic>\n            and 0.00125 to 0.0025 \u03bcg\/ml for\n            <jats:italic>C. pneumoniae<\/jats:italic>\n            . ABI-1648, ABI-1657, and ABI-1131 were 10- to 1,000-fold more active than azithromycin and levofloxacin.\n          <\/jats:p>","DOI":"10.1128\/aac.47.3.1135-1136.2003","type":"journal-article","created":{"date-parts":[[2003,2,25]],"date-time":"2003-02-25T18:22:21Z","timestamp":1046197341000},"page":"1135-1136","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":29,"title":["In Vitro Activities of Rifamycin Derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against\n            <i>Chlamydia trachomatis<\/i>\n            and Recent Clinical Isolates of\n            <i>Chlamydia pneumoniae<\/i>"],"prefix":"10.1128","volume":"47","author":[{"given":"Patricia M.","family":"Roblin","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, New York 11203-2098"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Reznik","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, New York 11203-2098"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Kutlin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, New York 11203-2098"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R.","family":"Hammerschlag","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, New York 11203-2098"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1072"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.1972-1976.2001"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.11.3001-3008.2001"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.7.1808"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.1118"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.7.1573"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"S556","DOI":"10.1093\/clinids\/5.Supplement_3.S556","volume":"5","year":"1983","unstructured":"Jones, R. B., G. L. Ridgway, S. Boulding, and K. L. Hunley. 1983. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis. Rev. Infect. Dis.5(Suppl. 3):S556-S561.","journal-title":"Rev. Infect. Dis."},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/244173a0","volume":"244","year":"1973","unstructured":"Keshishyan, H., L. Hanna, and E. Jawetz. 1973. Emergence of rifampin-resistance in Chlamydia trachomatis. Nature244:173-174.","journal-title":"Nature"},{"key":"e_1_3_1_10_2","first-page":"317","volume":"21","year":"1997","unstructured":"Kuo, C.-C., J. T. Grayston, T. Hidaka, and L. M. Rose. 1997. A comparison of the in vitro sensitivity of Chlamydia pneumoniae to macrolides and a new benzoxazinorifamycin, KRM-1648. Infect. Dis. Ther.21:317-321.","journal-title":"Infect. Dis. Ther."},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"S562","DOI":"10.1093\/clinids\/5.Supplement_3.S562","volume":"5","year":"1983","unstructured":"Schachter, J. 1983. Rifampin in chlamydial infections. Rev. Infect. Dis.5(Suppl. 3):S562-S564.","journal-title":"Rev. Infect. Dis."},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.8.1393"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.2.153"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.3.1135-1136.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.3.1135-1136.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:57:25Z","timestamp":1645466245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.3.1135-1136.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1128\/AAC.47.3.1135-1136.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.3.1135-1136.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3]]},"assertion":[{"value":"2002-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-11-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}